10-Q: CannaPharmaRx posts Q3 loss, flags going concern

CannaPharmaRx reported a Q3 2025 net loss, severe liquidity constraints, defaults under key agreements, and heavy related-party debt amid efforts to expand EU sales and secure financing.

Summary

• Revenue: $656,606 in Q3 2025 (up from $312,164 in Q3 2024); $1,223,533 for 9M 2025 (up from $338,003 in 9M 2024).
• Gross loss: $440,000 in Q3 2025; $1,563,817 for 9M 2025, driven by high COGS and $1,506,292 of inventory impairments YTD.
• Net income (loss): $(1,477,811) in Q3 2025 (vs. $188,421 in Q3 2024); $(3,581,863) for 9M 2025 (vs. $(6,164,948) in 9M 2024).
• Cash and liquidity: $927 cash at 9/30/2025; working capital deficiency of $27,009,769; accumulated deficit $104,766,005; shareholders’ deficit $(22,516,743).
• Balance sheet: Total assets $11,616,907; total liabilities $34,133,650, including $11,885,572 current related-party loans and $985,027 current lease liability.
• Debt restructuring: On 8/7/2025, interest on all outstanding promissory and convertible notes to Koze and Mr. Tal reset to 6% per annum; recognition of related extinguishment gains to APIC.
• Royalty and security: 3/17/2025 royalty agreement with Koze (CAD $0.20/gram; CAD $0.40 if late) secured by all ownership interest in subsidiary 2323414 Alberta Ltd.; in default as of 9/30/2025 with forbearance to 12/31/2025; royalty payable $287,035.
• Lease: 20-year lease amended 1/1/2025 to CAD $125,000/month; no lease payments made YTD with $804,457 unpaid and $1,056,096 accrued interest on rent in default.
• Customers: $574,001 Q3 sales to a German pharmaceutical company; $231,608 YTD sales to related party Cantek (Israel).
• Capital structure: 662,501,405 common shares outstanding as of 11/14/2025; 39,924,940 warrants outstanding; convertible notes $1,017,003 with derivative liability $556,755 and $735,002 of note penalties accrued.
• Controls: Management concluded internal controls over financial reporting were not effective due to a material weakness (turnover and incomplete documentation).
• Regulatory and insurance: Active Canadian cease trade order (CTO) remains; insurance coverage lapsed since early 2024.
• Legal matters: Ongoing claims include Ataraxia ($15M), Bristol Capital ($10.5M), former executives ($3M compensatory + $3M punitive; $917k accrued unpaid salaries), Deloitte fee claim (~$34k), and Astor Street (secured creditor with default judgment; asset seizure steps initiated 9/30/2025).

Sentiment

Score: 3

Explanation: Revenue growth and reduced debt rates are outweighed by severe liquidity stress, negative gross margins, defaults with short-dated forbearance, control weaknesses, lapsed insurance, and material legal exposures.

Positives

• Revenue growth: Q3 revenue of $656,606 more than doubled YoY; 9M revenue of $1,223,533 up >3x YoY.
• Debt cost reduction: Reset of related-party debt to 6% per annum on 8/7/2025 lowers ongoing interest burden.
• Geographic traction: Majority of Q3 revenue from a German pharmaceutical customer; YTD related-party sales into Israel indicate progress in target export markets.
• Derivative and obligation remeasurements: Non-cash gains of $602,569 (derivative) and $2,095,299 (obligation to issue shares) supported 9M 2025 results.
• Strategic plan: Intent to expand the Cremona facility from six to 10 grow rooms and pursue EU-GMP certification to streamline EU shipments.

Negatives

• Severe liquidity: $927 cash at 9/30/2025 and a working capital deficiency of $27,009,769.
• Negative profitability: Q3 net loss of $(1,477,811); persistent gross losses due to high COGS and inventory impairments ($1,506,292 YTD).
• Defaults and forbearance: Default under Koze royalty/security agreement with forbearance only until 12/31/2025; risk to ownership of subsidiary 2323414 Alberta Ltd.
• Lease and rent arrears: No lease payments made YTD; $804,457 unpaid lease expenses and $1,056,096 accrued interest on rent in default.
• Going concern uncertainty: Accumulated deficit of $104,766,005 and negative operating cash flow of $(1,850,544) YTD.
• Lapsed insurance: No insurance coverage since early 2024, elevating risk exposure.
• Legal overhang: Multiple lawsuits (Ataraxia $15M; Bristol $10.5M; former executives claims) and creditor enforcement (Astor Street asset seizure steps).
• Control weaknesses: Material weakness in internal control over financial reporting.
• Capital markets constraint: Active CTO in Canada restricts capital raising; significant reliance on related parties for financing.

Risks

• Substantial doubt about ability to continue as a going concern given minimal cash, large working capital deficit, and negative operating cash flows.
• Default under the Koze royalty/security agreement with forbearance only through 12/31/2025, secured by all ownership interest in 2323414 Alberta Ltd.
• Active Canadian cease trade order (CTO) limits equity issuance and conversions, constraining financing options.
• Lapsed insurance coverage since early 2024 exposes the company to uninsured liabilities and claims.
• Lease risk: No lease payments made in 2025; significant unpaid lease expenses and accrued interest in default.
• Convertible notes past maturity and penalty provisions accrued ($735,002).
• Legal exposures: Ataraxia claim ($15M), Bristol Capital claim ($10.5M), Deloitte fee claim, former executives’ lawsuit ($3M compensatory + $3M punitive; $917k accrued salaries), and Astor Street default judgment with steps to seize assets.
• Inventory impairment risk ($1,506,292 YTD) due to price compression, regulatory requirements, and sub-threshold THC potency.
• Material weakness in internal control over financial reporting due to turnover and incomplete records.
• Concentration and related-party risks: Significant reliance on Koze, Formosa, and Mr. Tal for financing, royalty, and lease arrangements.

Future Outlook

Plans include expanding the Cremona facility from six to 10 grow rooms over the next one to two years, opening a second drying/packing room, and pursuing EU-GMP certification to ship directly into the EU. Management intends to raise additional debt and/or equity to fund operations and growth. Under 8/7/2025 agreements, 60% of future profits and capital raised will be allocated to repay Koze and affiliates, with interest reset to 6% per annum. Management currently assesses a 100% probability of reaching $2,500,000 annual revenue by 11/22/2025 for the LTB earn-out and share true-up; however, liquidity constraints, the active CTO, and defaults pose material uncertainty.

Management Comments

• Plans to increase operations from six to 10 grow rooms over the next one to two years and open a second drying and packing room.
• Intends to apply for EU-GMP certification to reduce costs and shipping timelines for EU markets.
• There is substantial doubt about the ability to continue as a going concern without additional financing.
• Current financing is constrained by the Canadian CTO and is primarily reliant on related-party transactions.
• Internal control over financial reporting was not effective as of 9/30/2025 due to a material weakness arising from turnover and incomplete documentation; remediation plans are being developed.

Industry Context

Canadian cannabis producers face sustained price compression and a capital-constrained environment, pushing smaller operators to target higher-margin export channels such as Germany and Israel, where EU-GMP compliance is a key barrier to entry. CannaPharmaRx’s revenue ramp in Germany aligns with peer strategies, but persistent negative gross margins, defaults, and reliance on related-party financing highlight scale and cost challenges relative to larger GMP-certified competitors.

Comparison to Industry Standards

• Profitability: Larger Canadian LPs such as Tilray, Aurora Cannabis, and Organigram generally report positive gross margins on core operations; CannaPharmaRx posted a gross loss for Q3 and 9M 2025, reflecting sub-scale production and inventory impairments.
• EU Market Access: Established exporters (e.g., Tilray, Cronos) already hold EU-GMP certifications enabling direct EU shipments. CannaPharmaRx still intends to obtain EU-GMP and currently relies on third-party EU intermediaries, increasing costs and timelines.
• Liquidity and Leverage: Sector leaders maintain significantly greater cash and access to capital markets. CannaPharmaRx reported $927 in cash and a $27.0M working capital deficit, relying on related-party debt reset to 6%—an atypical dependency versus industry norms.
• Legal and Governance: While litigation is not uncommon in the sector, the combination of multiple active claims, an active CTO, lapsed insurance, and a reported material weakness in internal controls positions CannaPharmaRx below governance and risk management standards of more mature peers.

Management Changes

Legal Proceedings

• Ataraxia Canada, Inc.: Breach of contract claim related to AMS; seeks $15 million in damages; discussions ongoing.
• Bristol Capital Investors, LLC: California lawsuit alleging fraud and contract claims related to a purchase agreement; seeks $10.5 million plus fees; mediation and discussions ongoing.
• Deloitte LLP: Alberta civil claim for unpaid fees (~$33,997 reflected in payables).
• Former executives: Lawsuit for wrongful termination and unpaid compensation; $3M compensatory and $3M punitive sought; $917k accrued for unpaid salaries.
• Astor Street LLC: Default judgment in Canada; steps taken on 9/30/2025 to seize company assets; CAD $300,000 principal outstanding under secured notes.
• Cease Trade Order (CTO): Active order in Canada restricting trading and equity issuance; revocation application pending with BCSC (follow-up received 5/13/2025).

Related Party Transactions

• Royalty and security agreement with Koze (3/17/2025): CAD $0.20/gram royalty (CAD $0.40 if late) secured by 2323414 Alberta Ltd.; default with forbearance to 12/31/2025; $287,035 royalty payable.
• Lease with Formosa (related party since 3/11/2025): CAD $125,000/month after 1/1/2025 amendment; no payments in 2025 YTD; $804,457 unpaid lease and $1,056,096 accrued interest on rent in default.
• Debt to Koze and Mr. Tal reset to 6% on 8/7/2025; multiple notes extinguished and reissued; imputed interest recognized; balances outstanding across Koze LTB/A/B/C and convertible notes, and Mr. Tal LTB/CN.
• Promissory note with Formosa: $1,930,000 executed 1/1/2025, reset to 6% on 8/7/2025; $1,805,227 outstanding and $17,881 accrued interest at 9/30/2025.
• Sales to related party Cantek (100% owned by Koze; Mr. Tal advisor): $231,608 revenue YTD.
• Professional fees to Invictus Accounting Group LLP (CFO’s firm) and Fabian Vancott (director-affiliated law firm); marketing expense to Sky Home Services LLC (managed by Mr. Tal); office space formerly from entity affiliated with the board chair.

Stakeholder Impact

• Shareholders: Significant dilution risk from future capital raises; large shareholders’ deficit and going concern uncertainty.
• Creditors: Elevated default risk; security interests and forbearance may lead to asset seizures or loss of subsidiary.
• Employees: Reduced payroll and reliance on related-party services indicate cost pressure; litigation with former executives highlights HR risk.
• Customers: Supply reliability risk due to financial stress and inventory impairments; pursuit of EU-GMP could improve EU service levels longer term.
• Suppliers/Landlord: Accrued unpaid lease and payables signal counterparty risk.
• Regulators: Active CTO and internal control weaknesses increase regulatory scrutiny.

Next Steps

• Seek revocation of the Canadian CTO; continue engagement with BCSC.
• Pursue EU-GMP certification to enable direct EU shipments.
• Expand Cremona facility to 10 growing rooms and add a second drying/packing room.
• Adhere to 8/7/2025 repayment plans allocating 60% of profits and capital raised to debt service.
• Resolve lease and royalty arrears and avoid loss of subsidiary under Koze security.
• Remediate material weakness in internal controls over financial reporting.
• Manage legal proceedings (Ataraxia, Bristol, former executives, Deloitte) and negotiate resolution with Astor Street.
• Pursue additional financing (debt/equity) to address going concern.

Key Dates

Recommendation

Despite revenue growth and a lower interest burden on related-party debt, the capital structure and liquidity are acutely stressed (cash of $927; $27.0M working capital deficit), operations remain unprofitable with negative gross margins and sizable inventory impairments, and the company is in default under key agreements with forbearance expiring 12/31/2025. Lapsed insurance, material legal exposures, an active CTO limiting capital access, and a reported material weakness in internal controls materially elevate risk. Until financing is secured, defaults are cured, and gross margins turn positive, risk-adjusted returns appear unfavorable.

Keywords

CannaPharmaRx, cannabis cultivation, Germany cannabis export, Israel medical cannabis, EU-GMP certification, Koze Investments, Formosa Mountain, royalty agreement, lease liability, inventory impairment, convertible notes, derivative liability, forbearance, cease trade order, going concern, LTB Management, preferred stock Series C, related party transactions